Effects of Febuxostat Versus Allopurinol and Placebo in Reducing Serum Urate in Subjects With Hyperuricemia and Gout: A 28-Week, Phase III, Randomized, Double-Blind, Parallel-Group Trial

Effects of Febuxostat Versus Allopurinol and Placebo in Reducing Serum Urate in Subjects With Hyperuricemia and Gout: A 28-Week, Phase III, Randomized, Double-Blind, Parallel-Group Trial
复制标题

DOI：
10.1002/art.24209
复制
发表时间：
2008-11-15
期刊：
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH
影响因子：
--
通讯作者：
Joseph-Ridge, Nancy
Joseph-Ridge, Nancy
中科院分区：
其他
文献类型：
--
作者：
Schumacher, H. Ralph, Jr.;Becker, Michael A.;Joseph-Ridge, Nancy

文献摘要

被引文献

相似文献

Objective.比较非布司他、别嘌呤醇和安慰剂在包括肾功能损害患者在内的一大组高尿酸血症和痛风患者中的降尿酸疗效和安全性。高尿酸血症（血清尿酸水平>= 8.0 mg/dl）和痛风正常或受损（血清肌酐水平> 1.5至1.5 mg/dl）的受试者（n = 1，072）
Objective. To compare the urate-lowering efficacy and safety of febuxostat, allopurinol, and placebo in a large group of subjects with hyperuricemia and gout, including persons with impaired renal function.Methods. Subjects (n = 1,072) with hyperuricemia (serum urate level >= 8.0 mg/dl) and gout with normal or impaired (serum creatinine level > 1.5 to